Tharimmune (NASDAQ:THAR) Trading Down 2.1% – What’s Next?

Tharimmune, Inc. (NASDAQ:THAR) shares fell 2.1% during trading on Tuesday . The stock traded as low as $2.81 and last traded at $2.84. 148,283 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 1,106,134 shares. The stock had previously closed at $2.90.

Tharimmune Trading Down 2.1%

The company has a market cap of $16.76 million, a price-to-earnings ratio of -0.47 and a beta of 1.51. The stock’s 50 day moving average price is $2.89 and its 200 day moving average price is $1.95.

Tharimmune (NASDAQ:THAR) last released its earnings results on Thursday, August 14th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.06).

Institutional Investors Weigh In On Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. XTX Topco Ltd acquired a new position in Tharimmune, Inc. (NASDAQ:THAR) during the second quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,911 shares of the company’s stock, valued at approximately $25,000. XTX Topco Ltd owned 0.31% of Tharimmune at the end of the most recent reporting period. Institutional investors own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).